Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical relevance of JAK2 (V617F) mutant allele burden.

Literature DB >> 19118374

Clinical relevance of JAK2 (V617F) mutant allele burden.

Francesco Passamonti¹, Elisa Rumi.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2009 PMID： 19118374 PMCID： PMC2625431 DOI： 10.3324/haematol.2008.001271

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

23 in total

1. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.

Authors: A M Vannucchi; E Antonioli; P Guglielmelli; G Longo; A Pancrazzi; V Ponziani; C Bogani; P R Ferrini; A Rambaldi; V Guerini; A Bosi; T Barbui
Journal: Leukemia Date: 2007-07-12 Impact factor: 11.528

2. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera.

Authors: A Tefferi; J J Strand; T L Lasho; R A Knudson; C M Finke; N Gangat; A Pardanani; C A Hanson; R P Ketterling
Journal: Leukemia Date: 2007-05-03 Impact factor: 11.528

3. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.

Authors: A Tefferi; T L Lasho; J Huang; C Finke; R A Mesa; C Y Li; W Wu; C A Hanson; A Pardanani
Journal: Leukemia Date: 2008-01-24 Impact factor: 11.528

4. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.

Authors: Francesco Passamonti; Elisa Rumi; Marianna Caramella; Chiara Elena; Luca Arcaini; Emanuela Boveri; Cecilia Del Curto; Daniela Pietra; Laura Vanelli; Paolo Bernasconi; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal: Blood Date: 2008-01-10 Impact factor: 22.113

5. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.

Authors: Panayiotis D Ziakas
Journal: Haematologica Date: 2008-07-18 Impact factor: 9.941

6. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Authors: Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui
Journal: Blood Date: 2007-08-21 Impact factor: 22.113

7. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Authors: Ralph Tiedt; Hui Hao-Shen; Marta A Sobas; Renate Looser; Stephan Dirnhofer; Jürg Schwaller; Radek C Skoda
Journal: Blood Date: 2007-12-26 Impact factor: 22.113

8. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.

Authors: Elisabetta Antonioli; Paola Guglielmelli; Giada Poli; Costanza Bogani; Alessandro Pancrazzi; Giovanni Longo; Vanessa Ponziani; Lorenzo Tozzi; Lisa Pieri; Valeria Santini; Alberto Bosi; Alessandro M Vannucchi
Journal: Haematologica Date: 2008-01 Impact factor: 9.941

9. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

Authors: Animesh Pardanani; Brooke L Fridley; Terra L Lasho; D Gary Gilliland; Ayalew Tefferi
Journal: Blood Date: 2007-11-15 Impact factor: 22.113

10. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.

Authors: Valerio De Stefano; Tommaso Za; Elena Rossi; Alessandro M Vannucchi; Marco Ruggeri; Elena Elli; Caterina Micò; Alessia Tieghi; Rossella R Cacciola; Cristina Santoro; Giancarla Gerli; Nicola Vianelli; Paola Guglielmelli; Lisa Pieri; Francesca Scognamiglio; Francesco Rodeghiero; Enrico M Pogliani; Guido Finazzi; Luigi Gugliotta; Roberto Marchioli; Giuseppe Leone; Tiziano Barbui
Journal: Haematologica Date: 2008-02-11 Impact factor: 9.941

32 in total

1. A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations.

Authors: Hanna Janiszewska; Aneta Bak; Maria Pilarska; Marta Heise; Anna Junkiert-Czarnecka; Małgorzata Kuliszkiewicz-Janus; Małgorzata Całbecka; Bozena Jaźwiec; Dariusz Wołowiec; Kazimierz Kuliczkowski; Olga Haus
Journal: Haematologica Date: 2011-11-04 Impact factor: 9.941

2. Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Authors: Lisa A Raedler
Journal: Am Health Drug Benefits Date: 2014-10

3. Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.

Authors: Cornelis J J Huijsmans; Jeroen Poodt; Paul H M Savelkoul; Mirjam H A Hermans
Journal: J Mol Diagn Date: 2011-06-30 Impact factor: 5.568

4. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors: D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal: Leukemia Date: 2015-10-30 Impact factor: 11.528

Review 5. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors: Ruochen Jia; Robert Kralovics
Journal: Int J Hematol Date: 2019-11-18 Impact factor: 2.490

6. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation In Vivo.

Authors: Brittany Woods; Wei Chen; Sophia Chiu; Christian Marinaccio; Chunling Fu; Lilly Gu; Marinka Bulic; Qiong Yang; Anouar Zouak; Shengxian Jia; Praveen Kumar Suraneni; Kailin Xu; Ross L Levine; John D Crispino; Qiang Jeremy Wen
Journal: Clin Cancer Res Date: 2019-06-19 Impact factor: 12.531